Madrid

• A Study to Assess the Effectiveness of BOTOX (Botulinum Toxin Type A) Injections for the Change of Masseter Muscle Prominence in Adult Parti … Ended
  2022-500568-37-00 5 2023-10-11 Masseter Muscle Prominence
• A MULTICENTER, SINGLE-ARM, THREE COHORT, PHASE II TRIAL OF PATRITUMAB DERUXTECAN (HER3-DXD) IN PATIENTS WITH ACTIVE BRAIN METASTASES FROM HE … Ended
  2023-503251-10-00 4 2023-10-10 Metastatic Breast Cancer or Advanced Non-Small Cell Lung Cancer with a
• A study to test the effect of Samuraciclib in Combination with Elacestrant in Participants with Hormone Receptor-positive (HR+) and Human Ep … Ended
  2023-503846-30-00 9 2023-10-10 Breast Cancer
• A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adult … Ended
  2022-502552-31-00 4 2023-10-03 Relapsing Forms of Multiple Sclerosis
• A clinical study of bemcentinib with standard of care chemoimmunotherapy in untreated advanced/metastatic non-small cell lung cancer patient … Ended
  2024-511007-41-00 9 2023-10-03 Untreated advanced or metastatic non-squamous non-small cell lung canc
• Safety and efficacy of GSK Neisseria gonorrhoeae GMMA (NgG) investigational vaccine when administered to healthy adults 18 to 50 years of ag … Ended
  2022-500883-37-00 7 2023-10-02 This FTiH-PoC study aims to provide an early evaluation of the efficac
• Study of GS-4528 for Adults With Solid Tumors Ended
  2022-502070-16-00 1 2023-10-02 Solid Tumors
• A Phase 3, Open-label Study of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults with Tuberous Sclerosis Complex (TSC)-related Ep … Ended
  2022-503067-15-00 5 2023-10-02 Tuberous Sclerosis Complex (TSC) related epilepsy
• Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma (ALPHA2) Ended
  2022-501927-25-00 4 2023-09-29 Large B-Cell Lymphoma (LBCL)
• Phase 1 First-In-Human Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors Ended
  2022-502867-39-00 1 2023-09-29 Advanced solid tumors including non-small cell lung cancer (NSCLC), me
• Phase II, multi‑cohort trial of neoadjuvant and post‑surgery IO102‑IO103 and pembrolizumab in patients with selected resectable tumors Ended
  2022-502787-20-00 4 2023-09-28 Melanoma and squamous cell carcinoma of the head and neck
• Phase II trial of trastuzumab deruxtecan in first-line treatment HER2-positive locally advanced or metastatic breast cancer (MBC) patients c … Ended
  2023-503627-26-00 4 2023-09-28 Metastatic breast cancer
• A Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab (CDX-0159) in Adults with Active Eosinophilic Esophagitis (The … Ended
  2024-512767-30-00 4 2023-09-28 Eosinophilic Esophagitis
• A Phase 1 Study of PRT3789 in Participants with Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation Ended
  2022-502850-14-00 1 2023-09-25 gastroesophageal junction
• A Ph3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects with Severe Hypertriglyceridemia: The ENTRUST study Ended
  2023-503576-25-00 5 2023-09-22 Severe Hypertriglyceridemia
• Randomised, crossover bioequivalence clinical trial of montelukast 10 mg capsules vs montelukast 10 mg film-coated tablets, after a single o … Ended
  2023-506937-30-00 2 2023-09-20 Asthma
• CMV preemptive therapy in high-risk immunocompetent major heart surgery patients. A multicenter, double blind, randomized, clinical trial (G … Ended
  2022-501429-19-00 5 2023-09-19 Cytomegalovirus in high-risk immunocompetent major heart surgery.
• A double-blind, randomised, dose-finding trial to assess the efficacy, safety and pharmacokinetics of a single dose of albaconazole versus f … Ended
  2023-504727-32-00 4 2023-09-18 Acute vulvovaginal candidiasis
• A Study to Evaluate the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Pa … Ended
  2023-508489-14-00 4 2023-09-18 Solid Tumors
• A Phase 1 Study of BMS-986360/CC-90001 Alone and in Combination with Chemotherapy or Nivolumab in Advanced Solid Tumors Ended
  2022-500930-27-00 3 2023-09-15 Solid Tumor
• A Clinical Study that will measure how well SEP-363856 works and how safe it is in adults with Generalized Anxiety Disorder Ended
  2022-502077-42-00 10 2023-09-14 generalised anxiety disorder
• A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase III trial to evaluate efficacy and safety of secukinumab a … Ended
  2022-501895-25-00 5 2023-09-13 Polymyalgia Rheumatica
• Bioequivalence clinical trial of two formulations of ezetimibe/atorvastatin Ended
  2023-507226-16-00 2 2023-09-13 Healthy volunteers
• A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis Ended
  2022-501476-25-00 5 2023-09-12 Atopic Dermatitis Eczema

Showing 2,905–2,928 of 3,550 trials